AU2003295135A1 - Therapeutic agents - Google Patents

Therapeutic agents Download PDF

Info

Publication number
AU2003295135A1
AU2003295135A1 AU2003295135A AU2003295135A AU2003295135A1 AU 2003295135 A1 AU2003295135 A1 AU 2003295135A1 AU 2003295135 A AU2003295135 A AU 2003295135A AU 2003295135 A AU2003295135 A AU 2003295135A AU 2003295135 A1 AU2003295135 A1 AU 2003295135A1
Authority
AU
Australia
Prior art keywords
alkyl
amino
carbamoyl
heterocyclyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295135A
Other languages
English (en)
Inventor
Richard William Arthur Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003295135A1 publication Critical patent/AU2003295135A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003295135A 2002-12-24 2003-12-19 Therapeutic agents Abandoned AU2003295135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0230089.5 2002-12-24
GBGB0230089.5A GB0230089D0 (en) 2002-12-24 2002-12-24 Therapeutic agents
PCT/GB2003/005568 WO2004058776A1 (en) 2002-12-24 2003-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
AU2003295135A1 true AU2003295135A1 (en) 2004-07-22

Family

ID=9950374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295135A Abandoned AU2003295135A1 (en) 2002-12-24 2003-12-19 Therapeutic agents

Country Status (16)

Country Link
US (1) US20060069109A1 (https=)
EP (1) EP1575963B1 (https=)
JP (1) JP2006515593A (https=)
KR (1) KR20050087852A (https=)
CN (1) CN1751052A (https=)
AT (1) ATE394403T1 (https=)
AU (1) AU2003295135A1 (https=)
BR (1) BR0317708A (https=)
CA (1) CA2508917A1 (https=)
DE (1) DE60320849D1 (https=)
ES (1) ES2305548T3 (https=)
GB (1) GB0230089D0 (https=)
MX (1) MXPA05006921A (https=)
NO (1) NO20052989L (https=)
WO (1) WO2004058776A1 (https=)
ZA (1) ZA200504827B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
AU2015210454B2 (en) * 2005-12-23 2016-10-27 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
BRPI0710331A2 (pt) 2006-05-08 2012-03-20 Ariad Pharmaceuticals, Inc Compostos heteroarila monocíclicos para tratamento de câncer e composição
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
WO2008076883A2 (en) 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2365809B8 (en) 2008-11-12 2018-10-10 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2010144394A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Benzyl substituted triazine derivatives and their therapeutical applications
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
RU2014150494A (ru) * 2012-05-30 2016-07-20 Ф. Хоффманн-Ля Рош Аг Пирролидиногетероциклы
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2020333225B2 (en) 2019-08-16 2026-04-23 Cyclacel Limited Process for the preparation of a pyrimidino-diazepine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385747A1 (en) * 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
TR200201364T2 (tr) * 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
ES2289004T3 (es) * 2000-11-20 2008-02-01 Smithkline Beecham Corporation Nuevos compuestos.
ATE323702T1 (de) * 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Also Published As

Publication number Publication date
GB0230089D0 (en) 2003-01-29
ZA200504827B (en) 2006-04-26
NO20052989L (no) 2005-07-21
DE60320849D1 (de) 2008-06-19
WO2004058776A1 (en) 2004-07-15
US20060069109A1 (en) 2006-03-30
KR20050087852A (ko) 2005-08-31
ATE394403T1 (de) 2008-05-15
BR0317708A (pt) 2005-11-22
CA2508917A1 (en) 2004-07-15
CN1751052A (zh) 2006-03-22
EP1575963A1 (en) 2005-09-21
JP2006515593A (ja) 2006-06-01
MXPA05006921A (es) 2005-08-18
NO20052989D0 (no) 2005-06-17
EP1575963B1 (en) 2008-05-07
ES2305548T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
EP1575963B1 (en) Anti-angiogenetic therapeutic agents
US7427616B2 (en) Condensed pyridines and pyrimidines with tie2 (TEK) activity
US20080027076A1 (en) Pyrimidines With Tie2 (Tek) Activity
US20080194552A1 (en) Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
US20080153838A1 (en) Compounds Having Tie2 (Tek) Activity
US20080108608A1 (en) Pyrimidines With Tie2 (Tek) Activity
US20080146599A1 (en) Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
ES2393215T3 (es) Derivados de morfolino pirimidina útiles en el tratamiento de trastornos proliferativos
US20100048543A1 (en) Pyrimidine compounds having ties (tek) inhibitory activity
US7476677B2 (en) Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2
ES2354457T3 (es) Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
CN101151261A (zh) 具有tie2(tek)抑制活性的嘧啶化合物
HK1102045B (en) Pyrimidines with tie2 (tek) activity
HK1102425B (en) Pyrimidines with tie2 (tek) activity

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted